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Abstract: A series of 3-amino-2-ethoxycarbonyl pyrido[l,2-a]thieno[2,3-d]-4-pyrimidone 10-13 
were prepared in order to investigate their cytotoxicity and antimalarial activities. Some of the them 
showed a promising activity. The detailed synthesis, spectroscopic, computational and biological 
data are described. 
Introduction 
Structures such as [l,2-a]4-pyrimidone have been studied intensively due to their biological 
importance (1-3). The pharmacological activities and the therapeutic effects of some 
pyridopyrimidones have a wide application in clinic (2). As a part of our study directed toward the 
synthesis of tricyclic ring systems possessing a pyrido [1,2-a] pyrimidine nucleus, we reported the 
synthesis of some new pyrimidone derivatives as cytotoxic and antimalarial agents. 
Results and discussion 
2-ethoxycarbonyl-3-hydroxypyrido[l,2-a]thieno[2,3-d]-4-pyrimidone 14 has been obtained in a 
multistep procedure from ethyl 2-methylthio-4-oxo-4H-pyrido[l,2-a]pyrimidine-3-carboxylate 
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Recently, we have reported a general procedure for the synthesis and antimalarial activity of 3-
amino-pyrido[l,2-a] pyrazolo[2,3-d] pyrimidin-4-ones 15-18, by the reaction of the corresponding 
2-methylthio-pyrido[l,2-a]pyrimidine-4-oxo-3-carbonitrile derivatives 6-9 with hydrazine (3). 
No 15 16 17 18 
R Η 7-Me 8-Me 9-Me 
In view of the interesting biological activity exhibited by the above mentioned compounds, now we 
wanted to explore the effect caused by a modification on the fused hetrocyclic ring c by introducing 
a thiophene moiety. Thus, the synthesis of compounds 10-13 were accomplished by refluxing the 
corresponding nitriles 6-9 with an equimolecular amount of ethyl mercaptoacetate in the presence of 
sodium metoxide under an inert atmosphere of nitrogen. The reaction took place by a nucleophilic 
attack of thiolate anion on the carbon bearing the methylthio substituent, followed by a subsequent 
cyclization to afford compounds 10-13 as stable solids in good yields, as shown in the scheme 1. 
Scheme 1. 
E t o 2 a X N 
1 
"NHj MeS'^SMe ^ ΊΤ "SMe 
R ^ J ^ + II • R+- I II » R >—co2Et 
1-4 5 6-9 
a. n-butanol, Δ; b. HSCH2C02Et, Na, EtOH, Δ. 
No 10 11 12 13 
R Η 7-Me 8-Me 9-Me 
The starting nitriles 6-9 were prepared as previously described (3). The obtained compounds 10-13 
were fully characterized by their analytical and spectroscopical data. Thus, they showed the 
presence of an NH2 group in the IR spectra ( 3456-3438 cm"1), and a carbonyl from the ester (1696-
1705 cm"1). In the 1Η NMR spectra, the NH2 group appears at 6.87-6.89 ppm as a broad singlet. It is 
important to show that for compounds 11, 12 the methyl groups located at positions C7 and C8 
respectively appeared as doblets at 2.45-2.40 ppm with a J: 0.99 Hz, while in compound 13 this 
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coupling was not observed. Using NMR techniques, compounds 11, 12 were irradiated at the 
corresponding signals to Ηό at 8.74 ppm and H9 at 7.32 ppm affording enhancements on the of CH3 
signal, (20%) and (15%) respectively, and a disappearance of the doublet. This clearly indicated that 
the methyl groups at compounds 11, 12 were coupling with protons at 8.74 and 7.32 ppm 
respectively. These unexpected effects were not observed by us in previously synthesized 
compounds 16-18. Thus, for a better understanding of the above experimental results, we conducted 
a conformational and electronic study on the derivatives 10-13 and tiieir parent compounds 15-18. 
The purpose was to obtain more precise information about the stereoelectronic aspects that may aid 
in the understanding of the different accoupling obtained f^r these compounds in 'H NMR spectra. 
\A 
We determined the low-energy conformations of these compounds by molecular orbital calculations. 
Both semiempirical AMI and ab-initio (RHF 3-21G*) calculations, predict that the most stable 
forms are those in which the side-chain is located almost co-planar with respect to the rings system. 
Conformational potential energy surfaces (PES) of the compounds varing the torsional angles T1 vs 
T2 are shown in Figure 1 and 2. 
Observing these PESs it is clear that the conformational behavior of these compounds is very 
similar. The best way to take into account all of the possible electrostatic contributions is by means 
of the molecular electrostatic potential maps (MEPs), evaluated at ab-initio RHF/3-21G* level. 
Comparing these MEPs, at least two significative differences should be noted. The first is a 
different electronic distribution in the vicinity of the N-H group (ring c) of compounds 15-18 in 
comparison with that observed near to the sulphur group of compounds 10-13. The other is the 
different electronic distribution on the hydrogen atoms in (ring a). This is particularly evident after 
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examining the calculated partial charges in compounds 10-13 and 15-18 respectively. These results 
emphasize the importance of electronic effects rather than conformational factors in explaining the 
results observed in the *H NMR. The calculated partial charges are shown in Table 1. These 
molecular modeling results are in perfect agreement with the data obtained by irradiation 
spectrometric measurements. 
Table 1: Calculated Partial Charge for derivatives 10-13 and 15-18. 
Compound Cio Cn C n C n HIS H20 H2, H22 
10 0.005 -0.213 -0.057 -0.163 0.191 0.160 0.150 0.173 
11 -0.004 -0.147 -0.056 -0.159 0.191 - 0.149 0.173 
12 0.006 -0.212 0.008 -0.174 0.190 0.157 - 0.172 
13 -0.005 0.202 -0.070 -0.09Ϊ 0.193 0.160 0.149 -
15 0.005 -0.218 -0.056 -0.166 0.192 0.158 0.148 0.171 
16 0.000 -0.155 -0.054 -0.165 0.191 - 0.148 0.171 
17 0.007 -0.216 0.007 -0.175 0.191 0.157 - 0.171 
18 -0.002 -0.211 -0.067 -0.097 0.191 0.158 0.148 
The 13C NMR assignments were confirmed using a combination of DEPT 135° and 90°, and 
HETCOR experiments. The mass spectra showed the presence of the respective" mJz M1" (100% 
intensity) and a peak appearing in all cases at m/z: 257, corresponding to the lost of the Et20H group 
to form a stable ion. 
The cytotoxicity of compounds 10-13 were studied against the growth of Β16, MCF7, RD and FOG 
cancer cells, Vero (renal monkey cells) and primary culture from mouse and human fibroblast. The 
results are shown in Table 2. These data showed that compound 10 exhibited a significant 
cytotoxicity toward the above four cells lines. Compounds 11-13 exhibited a significant activity 
against the growth of RD cancer cells, and a moderate cytotoxicity toward Β16. Compounds 11-13 
were found to be inactive against Vero, MCF7 and FOG cell lines, mouse embryo fibroblast and 
human fibroblast. The above results indicate that the methyl group may be responsible for the 
selective cytotoxicity observed toward some cancer lines and that no methyl group presence increase 
the cytotoxic activity, which has been proposed by others (5), and further could be helpful in 
designing of new therapeutic agents. Preliminary antimalarial activity was evaluated against 
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Plamodium falciparum in vitro, and the results are shown in Table 3. These data show that 
compounds 10, 12, 13 exhibited significant activity against the inhibition of 3[H]-hypoxanthine 
incorporation at concentrations of lxlO"3 and lxlO^M. 
Table 2. Evaluation of the Cytotoxic Potential of Compounds (10-13). 
Cell lines LC50 ^g/ml) 
Compound HF MF Vero MCF7 B16 RD FOG 
10 60 55 60 98 » 1 0 0 » 1 0 0 » 1 0 0 
11 » 1 0 0 » 1 0 0 » 1 0 0 » 1 0 0 >100 50 >100 
12 » 1 0 0 » 1 0 0 >100 » 1 0 0 >100 61 » 1 0 0 
13 75 » 1 0 0 » 1 0 0 » 1 0 0 76 57 » 1 0 0 
HF: human fibroblast; MF: mouse fibroblast; Vero: renal monkey cells; MCF7: 
breast cancer; Β16: melanoma; RD: rabdomiosarcome; FOG: astrocitoma. 
Table 3. Evaluation of the Antimalarial Activity (lxlO3, lxlO"4 M)of compounds (10-13) against a 
chloroquine-resistant strain of Plasmodium falciparum. 
Compound % inhibition a % inhibition b 
10 8 2 7 1 
11 c c 
12 7 0 6 3 
13 8 3 
w t_ 7" 1 « 4 » „ 
81 
Experimental 
Melting points were determined in a Fisher melting point apparatus and are uncorrected. The IR 
spectra were recorded on a Shimadzu 470 spectrophotometer in KBr discs. The NMR spectra were 
recorded on a JEOL 270 MHz spectrometer using TMS as an internal standard. The chemical shifts 
are expressed as δ ppm. Mass spectra were obtained using an HP 5890 spectrometer with 70 eV 
ionization potential. Elemental analysis were obtained from Atlantic Microlab Inc (Norcross, GA) 
and are within ± 0.4% of the theoretical values. All chemicals and solvents were purchased from 
Aldrich Chemical. In the case where dry solvent were required, EtOH were destilled from Mg metal. 
Theoretical calculations were performed using the AMI semi-empirical method contained in the 
MOP AC package (6) and ab-initio RHF/3-21G* computations from the gaussian 94 suite of 
program (7). We made a complete molecular geometry optimization in each case, without any 
symmetry constraint, via the energy gradient method (8-10) contained in the gaussian 94 program. 
The electronic study of the molecules was carried out using Molecular Electrostatic Potentials 
(MEP) from the SPARTAN program (11). 
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Pyridof1,2-a]pyrimido-4-one 6-9. 
These compounds were obtained by following the method previously reported (3). 
General procedure for synthesis of 3-amino-2-ethoxycarbonylpyrido[ 1,2-aJthieno[2,3-d]pyrimido-
4-one derivatives 10-13. 
A mixture of the appropiate pyridopyrimidine 6-9 0.3g (1.3 mmol), ethyl 2-mercatoacetate 0.15g 
(1.3 mmol), sodium (0.04at/g) in dry ethanol (5 ml) was refluxed for 4 hours. The solvent was 
evaporated to dryness under reduced pressure, water was added (10 ml) and the solid thus obtained 
was colected by filtration. Further purification was accomplished by recrystalization from 
DMF/EtOH (1:3). 
3-amino-2-ethoxycarboylpyrido[l,2-a]thieno[2,3-d]pyrimido-4-one 10. 
The compound was obtained as yellow solid yield (83%), mp 186-187C; IR (KBr): 3456 (NH2), 
1699(C=0) cm'1; "Η NMR (CDCI3): 1,36(3H, t, CH2CH3, J: 7.2Hz), 4.30(2H, q, CH2CH3, J: 7.2Hz), 
6.88(2H, brs, NH2), 7.05(1H, dd, H8, J: 6.9Hz), 7.54(2H, d, H9, J: 8.9Hz), 7.70(1H, dd, H7, J: 6.9Hz), 
8.94(1H, d, Ηό, J:7.2Hz); 13C NMR: 14.24, 60.10, 91.25, 107.49, 114.43, 125.96, 127.19, 136.64, 
149.94, 151.39, 155.27, 165.16, 167.07; MS: m/z (intensity %) 289 (M+, 100%). 
Anal. Calcd. for C13H11N3O3S (289.32): C, 53.97; H, 3.83; N, 14.52. Found: C,53.80; H; 3.85; N, 14.54. 
3-amino-2-ethoxycarbonyl- 7-methylpyrido[ l,2-a]thieno[2,3-d]pyrimido-4-one 11. 
The compound was obtained as yellow solid yield (79%), mp 174-176C; IR (KBr): 3456 (NH2), 1693 
(C=0) cm"1; 'H NMR (CDCI3): 1.36(3H, t, CH2CH3, J: 7.2 Hz), 2.40(3H, d, CH3, J: 0.99Hz), 4.29(2H, 
q, CH2CH3, J: 7.2 Hz), 6.89(2H, brs, NH2), 7.48(1H, dd, H9, Jj: 9.2Hz, J2: 0.74Hz), 7.55(1H, dd, Hg, 
J,: 9.2Hz, J2: 2.0Hz), 8.74(1H, m, Ha,), 13C NMR: 14.22, 17.94, 60.07, 91.77, 107.44, 124.39, 124.75, 
125.36, 139.77, 149.02, 151.24, 155.24, 165.23,167.23; MS: m/z (intensity, %) 303 (M+, 100%). 
Anal. Calcd. for Q ^ N A S (303.34): C,55.43; H, 4.32; N, 13.55. Found: C, 55.12; H, 4,39; N, 13.67. 
3-amino-2-ethoxycarbonyl-8-methylpyrido[l,2-a]thieno[2,3-d]pyrimido-4-one 12. 
The compound was obtained as yellow solid yield (91 %), mp 239-240°C; IR (KBr): 3472 (NH2), 1705 
(C=0) cm"1; 'H NMR (CDCI3): 1.36(3H, t, CH2CH3, J: 7.2 Hz), 2.46(3H, d, CH3, J: 0.99Hz), 4.29(2H, 
q, CH2CH3, J: 7.2 Hz), 6.87(2H, brs, NH2), 6.88(1H, dd, H7, J,: 7.5Hz, J2: 1.7Hz), 7.32(1H, m, H9), 
8.84(1 H, d, H6, J: 7.5Hz), 13C NMR: 14.22, 21.24, 60.04, 91.70, 106.72, 117.27, 123.86, 126.45, 
149.16, 150.06, 151.58, 155.51, 166.52, 167.94; MS: m/z (intensity, %) 303 (M4", 100%). 
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Anal.Calcd. for C m H ^ Q j S (303.34): C, 55.43; H, 4.32; N, 13.55. Found: C, 55.10; H,4.35; N, 13.54. 
3-amino-2-ethoxycarbonyl-9-methylpyrido[l,2-a]thieno[2,3-d]pyrimido-4-one 13. 
The compound was obtained as yellow solid yield (87 %), mp 204-206 C; IR (KBr): 3483 (NH2), 
1696 ( C = 0 ) cm"'; 'H N M R (CDCI3): 1.36(3H, t, CH2CH3 , J: 7.2 Hz), 2.54(3H, s, CH3), 4.30(2H, q, 
CH2CH3 , J: 7.2 Hz), 6.87(2H, brs, NH2), 6.96(1H, dd, H7, J, : 6.9 Hz, J2: 7.2 Hz), 7.55(1H, dd, Hg, 
J,: 6.7Hz, J2: 1.5Hz), 8.86(1H, dd, He, J,: 7.2Hz, J2: 1.5Hz), 13C NMR: 14.25, 19.17, 60.23, 91.69, 
107.23, 119.35, 124.25, 126.18, 139.18, 150.19, 151.37, 155.36, 166.01, 167.78; MS: m/z (intensity, 
%) 303 (M+, 100%). 
Anal. Calcd. for C ^ a N A S (303.34): C, 55.43; H, 4.32; N, 13.55. Found: C, 54.91; H, 4.31; N, 13.55. 
Cytotoxicity, antimalarial testing. 
Β16, MCF7, RD, FOG cells were kindly provided by Laboratorie of Marie France Poupon, Institute 
Curie, Paris, France; and Vero cell line, mose embrion and human fibroblast cells were purchased 
from the Instituto de Biologia Experimental, Facultad de Ciencias, Universidad Central de 
Venezuela, Caracas, Venezuela. The cytotoxic activities of tested compounds against the above 
seven cell lines were assayed with a modification of the MTT [3-(4,5-dimethylthiazol-2-yl)-
diphenyltetrazolium bromide]colorimetric method (12). The cultured cells were treated at four 
concentration of pure test compound ranging from 10, 50, 100 and 400 μg/ml. All assays were 
performed in triplicate. The duration of the treatment was 24 h. The LC50 value was defined as the 
concentration of test compound resulting in a 50% reduction of absorbance compared to untreated 
cells in the MTT assay. 
The FCB1, a chloroquine-resistant strain, was originally obtained from a Colombian Patient, and 
maintained in continuos culture according to the techniques of Trager and Jensen (13). The culture 
was synchronized until ring trophozoytes using the method described by Lambros and Vanderberg 
(14). Drugs effects on P. falciparum proliferation were measured as inhibition of 3H-hypoxanthine 
incorporation into nucleic acid, using the method described by Desjardin (15). 
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